FDA seeking access to ADE data bases for adverse drug event analysis through $1.4 mil. grant program.
FDA SEEKS DATA BASES TO ADDRESS DRUG SAFETY QUESTIONS IN A TIMELY MANNER through a $1.4 mil. grant offered "for cooperative agreements to study adverse effects of marketed drugs, biologics and devices," a Feb. 5 Federal Register notice states. The agency expects to make four to six awards between $250,000 and $350,000 and hopes to find data bases "with a population of at least 2 mil. current enrollees." Applications are due by March 21.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth